OBI Pharmaceuticals

36 articles about OBI Pharmaceuticals

• OBI Pharma Announces Poster Presentations at the AACR 2024 Annual Meeting for OBI-992 and GlycOBI™ ADC platformPoster Presentations to highlight the latest research on OBI-992 (anti-TROP2 ADC) and OBI’s novel GlycOBI ADC platform

  3/18/2024

  OBI Pharma, Inc. announced preclinical data for OBI-992, a potential best-in-class anti-TROP2 Antibody-Drug Conjugate.

• OBI Pharma Announces Executive Leadership Management Change – Heidi Wang, Ph.D. Appointed as Chief Executive Officer

  6/2/2023

  Dr. Wang appointed by the OBI Pharma Board of Directors as Chief Executive Officer to lead OBI Pharma with a vision and to bring innovative cancer therapies to patients globally.

• OBI Pharma Announces Poster Presentations at AACR 2023 Annual Meeting for OBI-999 combination synergy with checkpoint inhibitor as well as Globo H-targeted CAR T-cell immunotherapy

  4/10/2023

  OBI Pharma, Inc. announced preclinical data demonstrating significant synergistic effects of OBI-999 and pembrolizumab in four different cancer models, as well as the potent antitumor effect of a chimeric antigen receptor T-cell immunotherapy targeting Globo H.

• OBI Pharma Announces Poster Presentations at the 2022 ASCO Annual Meeting for Adagloxad Simolenin, OBI-999, OBI-3424, and Exhibition Booth

  5/17/2022

  OBI Pharma, Inc. announced that data highlighting ongoing clinical studies targeting Globo H and AKR1C3 in different tumor types will be presented at the American Society of Clinical Oncology meeting from June 3–7, 2022 in Chicago, IL.

• OBI Pharma Announces Poster Presentations at AACR 2022 Annual Meeting for OBI-3424 and Globo H Science

  4/7/2022

  OBI Pharma, Inc. announced scientific data highlighting the antitumor synergy of OBI-3424 in combination with pembrolizumab and the association of high Globo H and PD-L1 expression resulting in poor survival in gastric cancer patients, will be presented at the American Association of Cancer Research Annual Meeting from April 8–13, 2022 in New Orleans, LA..

• OBI Pharma Enters License Agreement with Odeon Therapeutics for the Rights of OBI-999 and OBI-833 in China, Hong Kong and Macau

  2/22/2022

  OBI Pharma, Inc., a Taiwan biopharma company, and Odeon Therapeutics, a China biopharma company, have entered into an exclusive license agreement whereby OBI grants rights of OBI-999, a novel antibody-drug conjugate, and OBI-833, a therapeutic cancer vaccine, targeting the tumor antigen Globo H in China, Hong Kong and Macau to Odeon.

• OBI Pharma Announces Phase 2 Studies Patient Enrollment for OBI-999 and OBI-3424

  1/24/2022

  OBI Pharma, a Taiwan biopharma company, announced that the first patients have been enrolled in both of the Phase 2 studies of OBI-999, an antibody drug conjugate cancer therapy targeting Globo H, and OBI-3424, a prodrug targeting the enzyme aldo-keto reductase 1C3.

• OBI Pharma Announces First Patient Enrolled on SWOG Cancer Research Network's OBI-3424 Phase 1/2 Study Targeting AKR1C3 in T-ALL and T-LBL

  4/26/2021

  First clinical trial to evaluate the safety and efficacy of OBI-3424, a DNA alkylating agent targeting AKR1C3 enzyme, in T-Cell Acute Lymphocytic Leukemia and Lymphoblastic Lymphoma

• OBI Pharma Announces Poster Presentations at AACR 2021 Annual Meeting for OBI-3424, OBI-998, Globo H and SSEA-4

  4/6/2021

  Poster Presentations to highlight the latest research on OBI-3424 (AKR1C3 small molecule pro-drug), OBI-998 (SSEA-4 ADC) and the glycosphingolipid cancer antigens, Globo H and SSEA-4.

• OBI Pharma, Inc. to Present at the 39th J.P. Morgan Healthcare Conference

  1/6/2021

  OBI Pharma, Inc., a Taiwan biopharma company, announced that Tillman Pearce, MD., Chief Medical Officer, will present a company and clinical development overview at the 39th Annual J.P. Morgan Digital Healthcare Conference on Monday, January 11, 2021 at 11:00 a.m. EST/ 8:00 a.m. PST.

• OBI Pharma Announces Presentations at ESMO Asia 2020 Virtual Annual Meeting for OBI-833, a Novel Anti-Globo H Targeted Therapeutic Cancer Vaccine

  11/19/2020

  Presentations to highlight the OBI-833 Phase 1 clinical study results in non-small cell lung cancer (NSCLC) and the dose escalation cohort

• OBI Pharma Announces OBI-999 Presentation at 2020 World ADC Digital Meeting

  9/14/2020

  Presentation to highlight the scientific characteristics of the novel first-in-class anti Globo H antibody-drug conjugate (ADC), OBI-999

• OBI Pharma Announces Poster Presentations at AACR 2020 Virtual Annual Meeting II

  6/16/2020

  Poster Presentations to highlight the role of the Globo H antigen in cancer cell survival and its prevalence in different tumor types

• OBI Pharma Announces Poster Presentations at 2020 ASCO Virtual Annual Meeting for Adagloxad Simolenin, OBI-999 and OBI-3424

  5/20/2020

  Poster Presentations to highlight the ongoing clinical studies targeting Globo H and AKR1C3 antigens in different tumor types

• OBI Pharma Updates on Clinical Trial Activities During COVID-19 Pandemic

  4/8/2020

  OBI Pharma has been closely monitoring the impact of the COVID-19 pandemic worldwide.

• OBI Pharma Granted U.S. FDA Orphan Drug Designation for the Treatment of Gastric Cancer for Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999

  1/21/2020

  Second Orphan Drug Designation for OBI-999, a novel first-in-class Antibody-Drug Conjugate in combination with a validated payload and the antibody targeting Globo H, a glycolipid antigen found on multiple tumor types.

• OBI Pharma, Inc. to Present at the 38th Annual J.P. Morgan Healthcare Conference

  1/9/2020

  OBI Pharma, Inc., a Taiwan biopharma company, announced that Michael Chang, Ph.D. Chairman and CEO, will present a company overview at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2019 at 4:30 p.m. PST/ 7:30 p.m EST, in San Francisco, CA.

• OBI Pharma Granted FDA Orphan Drug Designation for the Treatment of Pancreatic Cancer for Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999

  12/26/2019

  First Orphan Drug Designation for OBI-999, a novel first-in-class Antibody-Drug Conjugate targeting Globo H, a glycolipid antigen found on multiple tumor types

• OBI Pharma Announces Initiation of a Phase 1/2 Study of Its Antibody-Drug Conjugate (ADC) Targeted Cancer Therapy, OBI-999

  12/18/2019

  OBI Pharma announced the initiation of a Phase 1/2 clinical trial of OBI-999, an antibody drug conjugate targeting Globo H, a glycolipid antigen overexpressed in multiple tumor types.

• OBI Pharma Announces U.S. FDA Clearance of IND Application for a Phase 1/2 Study of its Antibody-Drug Conjugate (ADC) targeted cancer therapy, OBI-999

  9/3/2019

  First Clinical Trial to test the Safety and Efficacy of based on an ADC (Antibody Drug Conjugate) targeting Globo H, a glycolipid antigen found on multiple tumor types   [03-September-2019]   TAIPEI, Taiwan , Sept. 3, 2019 /PRNewswire/ -- OBI Pharma, a Taiwan biopharma company (TPEx: 4174), today announced that the U.S. Food and Drug Administration (FDA) has cleared an